(Q61864712)
Statements
A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases (English)
0 references
26 January 2016
0 references
February 2019
0 references
82
0 references
2 year
0 references
80 year
0 references